First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Matthew Galsky

Status and phase: Terminated; Phase 2

Conditions: Transitional Cell Carcinoma; Urothelial Carcinoma; Bladder Carcinoma

Treatments: Drug: Paclitaxel; Drug: Everolimus

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01215136

HCRN GU10-147

Details and patient eligibility

About

The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.

Full description

OUTLINE: This is a multi-center study

Patients will be enrolled into one of two parallel cohorts:

• Cohort 1: impaired renal function AND poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily
• Cohort 2: impaired renal function OR poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 on D1, 8, 15

Restaging evaluations will be performed after every 2 cycles.

Treatment will continue until disease progression or unacceptable toxicity.

Karnofsky performance status 60-70%

Life Expectancy: Not specified

Hematopoietic:

• Absolute neutrophil count (ANC) ≥ 1.5 K/mm3
• Hemoglobin (Hgb) ≥ 9 g/dL
• Platelets ≥ 100 K/mm3
• INR ≤ 1.5 (Anticoagulants are allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of Low molecular weight (LMW) heparin for at least 2 weeks prior to registration for protocol therapy).
• Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L
• Fasting triglycerides ≤ 2.5 x ULN.
• Fasting serum glucose < 1.5 x ULN

Hepatic:

• Bilirubin ≤ 1.5 x ULN
• Aminotransferases (AST and ALT) ≤ 2.5 x ULN (unless liver metastases, then ≤ 5 x ULN)

Renal:

• Calculated creatinine clearance of < 60 using the Cockcroft-Gault formula

Cardiovascular:

• No symptomatic congestive heart failure of New York heart Association Class III or IV.
• No unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.

Enrollment: 36 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC.
• Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
• Must be ineligible for cisplatin, based on the following, within 30 days prior to registration for protocol therapy.
• Prior radiation therapy is allowed to < 25% of the bone marrow.
• Written informed consent and HIPAA authorization for release of personal health information.
• Age > 18 years at the time of consent.
• Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.
• Females of childbearing potential must have a negative pregnancy test within 7 days prior to prior to registration for protocol therapy.
• Females must not be breastfeeding.

Exclusion criteria

• No prior chemotherapy for metastatic disease. Prior chemotherapy in the neoadjuvant/adjuvant setting is allowed if completed at least 12 months prior to registration for protocol therapy.
• No active CNS metastases or leptomeningeal metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.
• No prior malignancy is allowed except for adequately treated basal cell or adequately treated squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers (treated definitively with no evidence of PSA progression), or other cancer for which the patient has been disease-free for at least 5 years.
• No treatment with any anticancer therapy or investigational agent within 30 days prior to registration for protocol therapy.
• No known hypersensitivity to any protocol treatment.
• No prior treatment with mTOR inhibitor (sirolimus, temsirolimus, everolimus).
• No history of immunization with attenuated live vaccines within one week prior to registration for protocol therapy or during study period.
• No severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air.
• No uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN.
• No active (acute or chronic) or uncontrolled severe infections.
• No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
• No known history of HIV seropositivity.
• No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
• No active, bleeding diathesis.
• No history of major surgery (defined as requiring general anesthesia) or significant traumatic injury within 30 days prior to registration for protocol therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

Cohort 1

Active Comparator group

Description:

Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)

Treatment:

Drug: Everolimus

Drug: Everolimus

Cohort 2

Active Comparator group

Description:

Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)

Treatment:

Drug: Paclitaxel

Drug: Everolimus

Drug: Everolimus